Johnson & Johnson raised 2026 guidance, but shares trade at 22.4 times earnings while $1.36 per share of scheduled 2027 transaction dilution and STELARA patent erosion stall forward earnings growth. Reiterate Sell with a $212.23 target.
Key points
- 22.4 times forward earnings prices in rapid acceleration that ignores disclosed pipeline acquisition dilution.
- $1.36 per share in scheduled 2027 transaction dilution offsets operational gains and keeps adjusted earnings essentially flat.
- 54.0% erosion in STELARA alongside pulsed-field ablation and surgery headwinds restricts organic top-line momentum.
The call
The stock trades at an unjustified valuation after running up over the past year. At $249.11, the price requires adjusted earnings to reach $13.84 per share in 2027 at a normal 18 times multiple, demanding 25% profit expansion. The market is too optimistic about operational momentum and discounts disclosed transaction dilution.
Adjusted diluted EPS trajectory and transaction dilution impact ($)- Reported / guided adjusted EPS
- Our forecast adjusted EPS
Source: Company filings and guidance disclosures through Q3 2026.
Underlying volume gains cannot outrun upcoming dilution. While DARZALEX and TREMFYA remain durable, STELARA losses and MedTech deceleration restrict operational sales growth to 6.0%. When combining operational profit expansion with management's guided $1.36 per share Firefly and Sail transaction drag, 2027 adjusted profit stalls near $11.17. Multiples will compress toward historical norms.
Valuation
| Valuation metric | Value |
|---|
| FY26E Adjusted Diluted EPS guidance midpoint | $11.10 |
| FY26E Pre-dilution baseline ($0.64 deal drag addback) | $11.74 |
| FY27E Pre-dilution EPS estimate (6.7% operational growth) | $12.53 |
| FY27E Transaction dilution (Firefly Bio and Sail Biomedicines) | ($1.36) |
| FY27E Adjusted Diluted EPS forecast | $11.17 |
| Target forward P/E multiple | 19.0× |
A 19.0 times multiple preserves a generous quality premium above the company's historical 16 to 18 times valuation band to reflect balance-sheet strength. At $249.11, the risk-reward skew is heavily asymmetric to the downside, supporting a Sell rating with a 14.8% forecast decline.
Risks
- Accelerating uptake of oral immunology launches like ICOTYDE and broad TREMFYA label expansion could outpace generic STELARA drag, visible in quarterly pharmaceutical disclosures.
- Global electrophysiology share could stabilize faster than anticipated via VARIPULSE regulatory approvals, measurable through quarterly MedTech segment performance updates.
- Failure of the proposed talc settlement to reach the 95% claimant participation threshold could re-expand litigation liabilities, tracked via multidistrict litigation docket filings.
What would change my mind
Operational pharmaceutical growth accelerating above 10% alongside management materially reducing its $1.36 per share 2027 transaction dilution framework would invalidate my bearish stance.